Navigation Links
Chimerix Joins International Network of Organizations to Cure Malaria
Date:4/2/2009

RESEARCH TRIANGLE PARK, N.C., April 2 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has joined the Medicines for Malaria Venture (MMV) and its network of public-private partnerships to discover, develop and facilitate the delivery of new, effective and affordable antimalarial drugs. The MMV will screen Chimerix' chemical library to identify activity against malaria, and any lead candidates that result will be developed in partnership with South African-based iThemba Pharmaceuticals.

"Chimerix has developed a proprietary approach to discovering compounds active against a broad range of viral diseases that we believe may be valuable in identifying compounds to combat malaria," said Dr. George Painter, CEO of Chimerix. "Malaria has been seen as an African epidemic, but really its impact is worldwide. As members of the global community, we are all responsible for contributing to the end of this disease. Further, by collaborating with iThemba, we can concomitantly support the growth and development of a sustainable biotech community in South Africa."

"The eradication of malaria is now at the top of MMV's agenda," stated Chris Hentschel, President and CEO of MMV. "We have reprioritized our research accordingly and are now placing greater emphasis on the urgent need to fill MMV's antimalarial R&D portfolio with promising, wholly new compounds that could be developed into highly effective drugs to treat malaria. We are delighted to be working with Chimerix and expect that this collaboration will result in exciting compounds that can not only treat malaria but also potentially tackle emerging resistance, stop malaria transmission, and target the rarer Plasmodium vivax malaria too."

"The intellectual and technological support from Chimerix is an important contribution to malaria research," said Dr. Dennis Liotta,
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
4. Van Andel Institute Joins the MetaMiner Oncology Partnership Program
5. Dan Blackshear Joins SteriFx Inc.
6. Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse
7. Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
8. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory
9. Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons
10. Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons
11. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Fla. (March 16, 2010)Pancreatic cancerknown as the most ... radical new therapy. A promising approach may come ... a therapeutic agent to kill cancerin a novel ... of Interventional Radiology,s 35th Annual Scientific Meeting in ... cancer offer minimal benefit, entirely new approaches are ...
(Date:3/16/2010)... Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... March 16 PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today ... ... , , ... ... ...
(Date:3/16/2010)... The Gynecologic Cancer Foundation (GCF) and the Claudia Cohen Research Foundation announce today that ... $50,000 GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher.  The prize is ... Cancer, meeting in San Francisco March 14-17, 2010 . , ... ... ...
Breaking Biology Technology:Going for gold with a novel interventional radiology treatment for pancreatic cancer 2Going for gold with a novel interventional radiology treatment for pancreatic cancer 3BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5
... Dec. 4 Delcath Systems, Inc. (Nasdaq: DCTH ) ... his position as a director of the Company, effective December 2, ... leave the Delcath board is a result of additional commitments to ... http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) , , ...
... a drug and diagnostic discovery company, is pleased to,announce ... (National Institute of,Industrial Property) during the last edition of ... "Since its inception, ExonHit consistently made ... intellectual property and in particular from its,international patents. The ...
... and PHILADELPHIA, Dec. 3 GlaxoSmithKline,(LSE/NYSE: GSK ) ... a,pending lawsuit in the previously announced tender offer to purchase ... Inc.,(Nasdaq: GNLB ), for $1.30 per share in ... It is a condition to ...
Other Biology Technology:Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 3GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3
(Date:3/16/2010)... 15, 2010-The emergence of biofuels into agricultural systems ... return while providing critical ecosystem services. Integrating perennial ... needs, but will require an understanding of biomass ... diversify their farms, farmers will need to know ... yield. , Landscape processes, such as hill slope ...
(Date:3/16/2010)... Scientists have unearthed the remains of one of the ... million year old fossil preserves the complete skeleton of ... known. Plumulitids were annelid worms - the group including ... deepest sea to the soil in your yard - ... of how this major group of organisms evolved. ...
(Date:3/16/2010)... is causing the largest die-off of great whales ever ... whale and health experts from the Wildlife Conservation Society ... sponsored by the International Whaling Commission on the Patagonian ... and urgent mystery. , At issue is the long-term ... world,s great conservation success stories and the focus of ...
Breaking Biology News(10 mins):The effect of landscape position on biomass crop yield 2Rare armor-plated creature discovered in Canada's capital 2Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3Guiding Healthcare Leaders Toward Just in Time Training 7947 1Guiding Healthcare Leaders Toward Just in Time Training 7947 2Guiding Healthcare Leaders Toward Just in Time Training 7947 3Guiding Healthcare Leaders Toward Just in Time Training 7947 4Guiding Healthcare Leaders Toward Just in Time Training 7947 5Short on specialized intensive care physicians team based approach improves ICU outcomes 67143 1Short on specialized intensive care physicians team based approach improves ICU outcomes 67143 2Do TV ads affect childrens diet obesity 3F 11980 1Do TV ads affect childrens diet obesity 3F 11980 2
... promising news about pancreatic cancer, one of the most ... and the lack of effective therapies: Johns Hopkins University ... receptor aberrantly active in approximately a third of the ... In a presentation April 18, at Experimental Biology 2009 ...
... a key genetic mechanism at work in bacteria, including some ... the design of a new class of antibiotics, according to ... of the week" in the Journal of Biological Chemistry ... proteins, the workhorse molecules that make up the body,s structures ...
... sea water, but hidden under an inland Antarctic glacier, appears ... a most unexpected setting to be teeming with life. ... of animals and complex plants and scientists consider them to ... receive, on average, only 10 cm (3.93 inches) of snow ...
Other Biology News:Newly discovered epidermal growth factor receptor active in human pancreatic cancers 2Genetic switch potential key to new class of antibiotics 2Genetic switch potential key to new class of antibiotics 3Genetic switch potential key to new class of antibiotics 4Genetic switch potential key to new class of antibiotics 5Genetic switch potential key to new class of antibiotics 6Unlikely life thriving at Antarctica's Blood Falls 2Unlikely life thriving at Antarctica's Blood Falls 3
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
Prepared in 0.85% saline....
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
Biology Products: